Ryanair Wins U.S. Court Case Against Booking.com
By Pierre Bertrand
Ryanair said Friday that it has won a case in the U.S. against Booking.com and that the jury in the state of Delaware dismissed the online travel company's counter claims against the low-cost airline.
Ryanair said jurors on Thursday evening unanimously ruled in favour of its claims that Booking.com had violated the U.S. Computer Fraud and Abuse Act, causing loss to Ryanair.
"The jury also ruled that Booking.com had done so knowingly with 'intent to defraud', and that Ryanair had suffered economic harm as a result of Booking.com's unlawful screenscraping activity," Ryanair said.
Booking.com wasn't immediately available for comment when approached by Dow Jones Newswires.
Ryanair added that the Delaware Court jury, in addition, dismissed all of Booking.com's counterclaims against Ryanair, including claims of defamation, unfair competition and deceptive trade practices.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
July 19, 2024 08:27 ET (12:27 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States